Bayer Pharmaceuticals Corporation
72Patents
10Active
72Granted
39Portfolio score
Filing activity: Sep 30, 1994 → Mar 13, 2013 · 8 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6955807B1 | IL-2 selective agonists and antagonists | Human Necessities | 96 | Expired |
| US6689353B1 | Stabilized interleukin 2 | Human Necessities | 67 | Expired |
| US7329670B1 | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas | Chemistry; Metallurgy | 49 | Expired |
| US7235576B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | Chemistry; Metallurgy | 47 | Expired |
| US7351834B1 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | Chemistry; Metallurgy | 40 | Expired |
| US7041646B2 | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists | Human Necessities | 33 | Expired |
| US6670175B2 | Cryopreservation bag assembly for mammalian cell lines | Emerging Cross-Sectional Technologies | 30 | Expired |
| US6689582B1 | Polynucleotide molecules encoding proteins having proteinase inhibitor activity | Human Necessities | 29 | Expired |
| US7528255B2 | Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors | Chemistry; Metallurgy | 25 | Expired |
| US6849638B2 | 4-AMINO-5,6-SUBSTITUTED THIOPHENO [2,3-D] PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND THEIR USE IN THE TREATMENT OR PREVENTION OF PDE7B-MEDIATED DISEASES AND CONDITIONS | Chemistry; Metallurgy | 21 | Expired |
| US7517880B2 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | Emerging Cross-Sectional Technologies | 18 | Expired |
| US6784167B2 | 17-beta-hydroxysteroid dehydrogenase-II inhibitors | Chemistry; Metallurgy | 18 | Expired |
| US7511041B2 | Fused azole-pyrimidine derivatives | Chemistry; Metallurgy | 18 | Expired |
| US6972319B1 | Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use | Human Necessities | 16 | Expired |
| US6864069B2 | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use | Human Necessities | 15 | Expired |
| US7371763B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | Human Necessities | 14 | Expired |
| US6660752B2 | 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists | Chemistry; Metallurgy | 12 | Expired |
| US6960601B2 | Preparation and use of imidazole derivatives for treatment of obesity | Chemistry; Metallurgy | 10 | Expired |
| US7563791B2 | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | Chemistry; Metallurgy | 8 | Expired |
| US7244616B2 | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells | Chemistry; Metallurgy | 8 | Expired |
| US7091228B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | Chemistry; Metallurgy | 8 | Expired |
| US6903101B1 | Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity | Chemistry; Metallurgy | 7 | Expired |
| US7098207B2 | Imidazotriazinones and the use thereof | Human Necessities | 7 | Expired |
| US6689883B1 | Substituted pyridines and pyridazines with angiogenesis inhibiting activity | Chemistry; Metallurgy | 7 | Expired |
| US6828335B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | Emerging Cross-Sectional Technologies | 6 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.